STOCK TITAN

Vanda Pharmaceuticals to Announce Second Quarter 2020 Financial Results on August 5, 2020

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags

WASHINGTON, July 29, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the second quarter 2020 on Wednesday, August 5, 2020, after the market closes.

Vanda will host a conference call at 4:30 PM ET on Wednesday, August 5, 2020, during which management will discuss the second quarter 2020 financial results and other corporate activities. To participate in the conference call, please dial 1-888-771-4371 (domestic) or 1-847-585-4405 (international) and use passcode 49854840.

The conference call will be broadcast simultaneously and archived on Vanda's website, www.vandapharma.com. Investors should go to the website at least 15 minutes early to register, download, and install any necessary audio software.

About Vanda Pharmaceuticals Inc.

Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on Twitter @vandapharma.

Corporate Contact:
AJ Jones II
Chief Corporate Affairs and Communications Officer
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com

Elizabeth Van Every
Head of Corporate Affairs
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com

Cision View original content:http://www.prnewswire.com/news-releases/vanda-pharmaceuticals-to-announce-second-quarter-2020-financial-results-on-august-5-2020-301102555.html

SOURCE Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc

NASDAQ:VNDA

VNDA Rankings

VNDA Latest News

VNDA Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
US
Washington

About VNDA

vanda is a specialty pharmaceutical company focused on the development and commercialization of novel therapies to address high unmet medical needs and improve the lives of patients.